XORTX Therapeutics warns of going-concern doubt as cash falls to $318,846
The gout and kidney disease developer reports a nine-month net loss of about $2.88M, after a share consolidation and a voluntary TSX Venture delisting.
16 Nov 2026 · XORTX Therapeutics Inc. XRTX · Company news
XORTX Therapeutics, a late-stage company developing therapies for gout and kidney disease, has filed unaudited interim financial statements for the nine months ended 30 September 2026. The statements show a net loss of about $2.88M and cash of $318,846.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): XORTX Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More IndustryAll →
Industry
iMDx Pauses FDA De Novo Review of GraftAssureDx Kidney Rejection Test, Plans January Response
16 Nov 2026 · Insight Molecular Diagnostics Inc. IMDX · Company news
Industry
Cumberland to file ifetroban NDA for Duchenne cardiomyopathy under FDA rolling submission
16 Nov 2026 · Cumberland Pharmaceuticals Inc CPIX · Company news
Industry
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
16 Nov 2026 · Unicycive Therapeutics, Inc. UNCY · Company news
Industry
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
16 Nov 2026 · Noema Pharma AG · Company news
Industry
Sono Group updates share counts ahead of 11 December redomiciliation vote
16 Nov 2026 · Sono Group N.V. SSM · Company news
Industry
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
16 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news